Latest News

Date Title Topic
22 Oct 2013 Mutational Landscape Identified in 12 Major Cancer Types Translational research
21 Oct 2013 Spanish Researchers Sequence Non-infiltrating Bladder Cancer Exome Genitourinary cancers - Translational research
17 Oct 2013 Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Patients With Node-Positive Breast Cancer Breast cancer
16 Oct 2013 Hitting Angiogenesis in Gastric Cancer Gastrointestinal cancers - Anticancer agents & Biologic therapy
14 Oct 2013 Adjuvant Chemotherapy with Gemcitabine for Resected Pancreatic Cancer Gastrointestinal cancers
01 Oct 2013 ESMO @ ECC 2013: Addition of Trebananib to Paclitaxel Significantly Increases Progression-free Survival in Women with Recurrent Epithelial Ovarian Cancer Gynaecologic malignancies
01 Oct 2013 ESMO @ ECC 2013: Primary Endpoint Unmet in a Phase III Trial of First-Line Treatment with Palifosfamide plus Doxorubicin in Patients with Metastatic Soft Tissue Sarcoma Sarcomas
01 Oct 2013 ESMO Press Release: More Research Urged to Compare and Validate Genomic Tests in Oncology - ESMO Press Commentary Personalised medicine
01 Oct 2013 ECC 2013 Press Release: Variations in Death Rates after Surgery for Oesophageal and Gastric Cancers Prompt European Initiative to Improve Patient Outcomes Gastrointestinal cancers
30 Sep 2013 ECC Press Release: The State of Oncology 2013 – New Report Draws Attention to Urgent Need to Tackle Disparities in Cancer Care Worldwide Bioethics, legal and economic issues
30 Sep 2013 ESMO @ ECC 2013: Cediranib Shows Benefit in Women with Relapsed, Platinum-Sensitive Ovarian Cancer (ICON6) Gynaecologic malignancies
30 Sep 2013 ESMO @ ECC 2013: No Benefit Seen from Adding Zalutumumab to Radiotherapy in Patients with Squamous Cell Carcinoma of the Head and Neck Head and neck cancers
30 Sep 2013 ECC 2013 Press Release: Biological Therapy with Cediranib Improves Survival in Women with Recurrent Ovarian Cancer Gynaecologic malignancies - Anticancer agents & Biologic therapy
30 Sep 2013 ESMO @ ECC 2013: Targeted Treatment Options May Arise from Molecular Profiling of Patients with Cancers of Unknown Primary Site Carcinoma of unknown primary site